Brokerages Set Revance Therapeutics, Inc. (NASDAQ:RVNC) Price Target at $11.50

Revance Therapeutics, Inc. (NASDAQ:RVNC) has been given a consensus recommendation of “Moderate Buy” by the eight research firms that are currently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $11.50.

Several equities research analysts recently issued reports on RVNC shares. Piper Sandler reiterated an “overweight” rating and set a $11.00 price target (down previously from $20.00) on shares of Revance Therapeutics in a report on Friday, May 10th. HC Wainwright decreased their price target on Revance Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a report on Monday, May 13th. Needham & Company LLC decreased their price target on Revance Therapeutics from $18.00 to $12.00 and set a “buy” rating for the company in a report on Friday, May 10th. The Goldman Sachs Group decreased their price target on Revance Therapeutics from $9.00 to $8.00 and set a “neutral” rating for the company in a report on Monday, May 13th. Finally, Barclays decreased their price target on Revance Therapeutics from $35.00 to $10.00 and set an “overweight” rating for the company in a report on Monday, January 29th.

Revance Therapeutics Stock Up 1.5 %

NASDAQ RVNC opened at $2.71 on Tuesday. The company has a market cap of $283.06 million, a price-to-earnings ratio of -0.75 and a beta of 1.16. Revance Therapeutics has a 52 week low of $2.63 and a 52 week high of $32.45. The business has a 50 day moving average price of $4.01 and a 200-day moving average price of $5.76.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.17. The firm had revenue of $69.80 million for the quarter, compared to the consensus estimate of $64.02 million. On average, equities research analysts anticipate that Revance Therapeutics will post -1.83 earnings per share for the current year.

Insider Buying and Selling at Revance Therapeutics

In other Revance Therapeutics news, CFO Tobin Schilke sold 9,361 shares of the company’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $5.04, for a total value of $47,179.44. Following the completion of the transaction, the chief financial officer now owns 192,666 shares in the company, valued at approximately $971,036.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Tobin Schilke sold 9,361 shares of the company’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $5.04, for a total transaction of $47,179.44. Following the transaction, the chief financial officer now owns 192,666 shares of the company’s stock, valued at approximately $971,036.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Dwight Moxie sold 8,125 shares of the company’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $5.04, for a total value of $40,950.00. Following the transaction, the insider now directly owns 137,815 shares in the company, valued at approximately $694,587.60. The disclosure for this sale can be found here. Insiders sold 29,089 shares of company stock worth $143,642 in the last quarter. 5.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Revance Therapeutics by 17.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,083 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 2,622 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in Revance Therapeutics by 55.2% during the 3rd quarter. Principal Financial Group Inc. now owns 963,029 shares of the biopharmaceutical company’s stock worth $11,046,000 after purchasing an additional 342,540 shares in the last quarter. Los Angeles Capital Management LLC lifted its holdings in Revance Therapeutics by 122.5% during the 3rd quarter. Los Angeles Capital Management LLC now owns 18,976 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 10,446 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in Revance Therapeutics during the 3rd quarter worth about $4,749,000. Finally, Fox Run Management L.L.C. purchased a new stake in Revance Therapeutics during the 3rd quarter worth about $211,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.